Anxiety Disorders and Depression Treatment Market – Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2020

According to the World Health Organization (WHO), depression and anxiety disorders, including stress-related psychiatric conditions, would rival cardiovascular diseases by 2020 as the major health disorder with the highest disease burden globally. Antidepressants and anxiolytics are the medications used to treat various types of depression and anxiety disorders and prevent them from recurring. Anxiety is a natural reaction to stress, trauma and fear, which can be experienced by everyone at times. However, when this condition becomes severe, it might challenge an individual’s capability to lead a normal life. Similarly, depression is a state of low mood and aversion to daily activities that can affect an individual’s feelings, thoughts, sense of well-being and behavior. Various researches reveal that anxiety disorders and depression are the major risk factors for suicide among humans. Over 90% of individuals who commit suicide have some sort of diagnosable mental illness. It has also been reported that depression and anxiety disorders are more prevalent in developed economies such as the U.S., Canada, France, Germany, the U.K., and Italy due to the high levels of work-associated stress, personal relationships, societal factors, environmental factors as well as genetic aspects prevalent in these geographies.

Presently, the global anxiety disorders and depression treatment market is on a decline due to patent expiry of major antidepressants, weak pipeline of novel drugs and increasing number of generic drug variants. However, driving factors such as increasing prevalence of anxiety disorders and depression and rising geriatric population prone to psychiatric disorders are expected to offset the declining growth of the market in the near future.

Download Complete PDF Brochure:

The anxiety disorders and depression treatment market has been segmented based on drug classes most commonly used for the treatment and prevention of psychiatric disorders. Based on drug classes, the market has been segmented into selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCA), monoamine oxidase inhibitors (MAOIs), benzodiazepines, atypical antipsychotics, anticonvulsants and beta blockers. SNRIs accounted for the largest share of the depression treatment market in 2013. However, the segment is expected to witness a decline in revenue during the forecast period. Patent expirations of leading branded formulations such as Cymbalta and Effexor XR coupled with growing influx of generic formulations are some of the major factors expected to affect the growth of the segment. Similarly, SSRIs accounted for the largest share of the anxiety disorders treatment market in 2013. However, the market for SSRIs is expected to decline due to patent expirations, growing prevalence of treatment-resistant psychiatric disorders and high adoption rate of generic drugs.

North America is the largest market for anxiety disorders and depression treatment drugs due the presence of large patient population suffering from various types of anxiety disorders and depression. However, the anxiety disorders and depression treatment market in the U.S. is currently saturated, as several antidepressant drugs are available on prescription for the same indication. Hence, the future growth of the market would depend on introduction of efficacious drugs for new indications. Moreover, loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles are the additional factors that contribute to the decline in market growth in the region. Asia Pacific is expected to witness an appreciable growth due to multiple factors such as high prevalence of psychiatric disorders and rapid economic growth in countries such as China, Japan and Australia. Additionally, positive marketing approval for innovative medicines is likely to drive the market in the near future.

Browse Full Research Report:

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.


Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Browse market research blog:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s